Omapatrilat — the ups and downs of an exciting but complicated new drug
- 12 June 2000
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 74 (1) , 1-3
- https://doi.org/10.1016/s0167-5273(00)00294-1
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Effect of mibefradil on heart rate variability in patients with chronic heart failureInternational Journal of Cardiology, 2000
- Angioedema due to ACE inhibitors: increased risk in patients of African originBritish Journal of Clinical Pharmacology, 1999
- Vasopeptidase Inhibition with Omapatrilat Improves Cardiac Geometry and Survival in Cardiomyopathic Hamsters More Than Does ACE Inhibition with CaptoprilJournal of Cardiovascular Pharmacology, 1999
- Heart failure 99 — the Moxcon storyInternational Journal of Cardiology, 1999
- Angioedema due to angiotensin-converting enzyme inhibitorsImmunopharmacology, 1999
- Potential risk of β-blockade withdrawal in congestive heart failure due to abrupt autonomic changesInternational Journal of Cardiology, 1999
- OmapatrilatDrugs in R&D, 1999
- Plasma bradykinin in angio-oedemaThe Lancet, 1998
- Treating chronic heart failure: time to take stockThe Lancet, 1997
- Randomised study of effect of ibopamine on survival in patients with advanced severe heart failureThe Lancet, 1997